GlassScriptPhysician profile
Julie Widmar
NPI 1669148912
$12,090.69
in general payments reported to CMS, 2019-2025
13 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $1,031 · 2023: $5,027 · 2024: $5,418 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,040 · Honoraria: $2,640 · Food and Beverage: $2,118 · Travel and Lodging: $2,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,040.00 |
| Honoraria | $2,640.00 |
| Food and Beverage | $2,117.54 |
| Travel and Lodging | $2,039.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,620.64 | 2024 | Uplizna |
| Horizon Therapeutics Plc | $3,996.83 | 2022-2023 | Uplizna |
| Biogen, INC. | $1,075.70 | 2021-2025 | Tysabri, Vumerity, Plegridy |
| Tg Therapeutics, INC. | $697.85 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $474.21 | 2022-2025 | |
| Genzyme Corporation | $336.28 | 2021-2025 | |
| Emd Serono, INC. | $289.72 | 2022-2023 | Mavenclad |
| Celgene Corporation | $267.19 | 2021-2023 | Zeposia |
| Genentech, INC. | $178.20 | 2022-2023 | Ocrevus |
| Banner Life Sciences, LLC | $64.48 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.05 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.92 | 2022 | |
| Sandoz INC. | $22.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Widmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.